Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aluminium hydroxide + magnesium hydroxide + oxetacaine
- Development stage
- Unknown
- Lead developer
- New Marketlink Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Ducid Plus is an oral fixed-dose combination antacid and local anesthetic product containing aluminium hydroxide, magnesium hydroxide, and oxetacaine (also known as oxethazaine). Originally developed by Wyeth (now Pfizer) under the brand name Mucaine, and distributed in the Philippines by New Marketlink Pharmaceutical, it is indicated for the symptomatic relief of acute and chronic gastritis, duodenal ulcers, esophagitis, and dyspepsia. Aluminium hydroxide and magnesium hydroxide act as antacids, neutralizing excess gastric acid in the stomach to alleviate heartburn and hyperacidity. Oxetacaine is a potent, acid-stable local anesthetic that provides rapid and prolonged pain relief by temporarily numbing the mucosal lining of the esophagus and stomach. This combination effectively balances the gastrointestinal side effects of the antacids (constipation from aluminium and diarrhea from magnesium) while providing immediate local anesthetic relief.
- Brand names
- Ducid Plus
- Other names
- aluminium hydroxide + magnesium hydroxide + oxetacainealuminium hydroxide + magnesium hydroxide + oxethazainealuminum hydroxide + magnesium hydroxide + oxetacainealuminum hydroxide + magnesium hydroxide + oxethazaine
02
Targets
PEP (Pepsin)NaV (Voltage-gated sodium channels)
Beyond the preview
Go deeper on aluminium hydroxide + magnesium hydroxide + oxetacaine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aluminium hydroxide + magnesium hydroxide + oxetacaine.